Craig William Ritchie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Craig William Ritchie has a total of 591 co-authors. Here are the top co-authors by number of shared publications:
- Graciela Muniz-Terrera
Ohio University
27 shared publications - John Tiernan O'Brien
Department of Psychiatry, University of Cambridge, UK
18 shared publications - Maria‐Eleni Dounavi
Department of Psychiatry, University of Cambridge, Cambridge United Kingdom
17 shared publications - Ivan Koychev
Imperial College London
14 shared publications - Paresh Malhotra
Imperial College London
14 shared publications - Juan Domingo Gispert
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation
13 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by MDPI AG in Preprints.org
The Role of Cortisol in CNS Disease –11β-HSD1 Inhibition as a Potential New Therapeutic Strategy for Alzheimer’s Disease and Major Depressive Disorder
Cortisol is primarily synthesized by the adrenal glands, but also within specific tissues via a distinct enzymatic pathway. 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalyses the synthesis of cortisol within cells to create local higher cortisol environments in those organs where it is highly expressed such as the liver and brain. An extensive preclinical and clinical literature suggests that chronically, excess cortisol is detrimental. Since 11β-HSD1 expression rises with ageing, contributes to cognitive and affective disorders, and is strongly associated with Alzheimer’s disease, 11β-HSD1 inhibitors may plausibly treat cognitive and functional decline in Alzheimer’s disease and improve depression. Two inhibitors (ABT-384 and emestedastat) were studied in 12-week trials in patients with clinically diagnosed, unconfirmed Alzheimer’s disease (AD) and showed no overall benefits as a cognitive enhancer. When a subgroup with elevated blood pTau181 was later evaluated in the emestedastat trial, a slowing in progression was observed. A trial of emestedastat treatment has also reported anti-depressant activity. Thus, 11β-HSD1 inhibition appears to be a viable therapeutic mechanism. A pivotal, confirmatory trial of emestedastat treatment in 247 patients with mild-moderate AD is due to report topline results in November this year.
- 16 October 2026
- Published by MDPI AG in Preprints.org
Open AccessThe Role of Cortisol in CNS Disease –11β-HSD1 Inhibition as a Potential New Therapeutic Strategy for Alzheimer’s Disease and Major Depressive Disorder
Cortisol is primarily synthesized by the adrenal glands, but also within specific tissues via a distinct enzymatic pathway. 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalyses the synthesis of cortisol within cells to create local higher cortisol environments in those organs where it is highly expressed such as the liver and brain. An extensive preclinical and clinical literature suggests that chronically, excess cortisol is detrimental. Since 11β-HSD1 expression rises with ageing, contributes to cognitive and affective disorders, and is strongly associated with Alzheimer’s disease, 11β-HSD1 inhibitors may plausibly treat cognitive and functional decline in Alzheimer’s disease and improve depression. Two inhibitors (ABT-384 and emestedastat) were studied in 12-week trials in patients with clinically diagnosed, unconfirmed Alzheimer’s disease (AD) and showed no overall benefits as a cognitive enhancer. When a subgroup with elevated blood pTau181 was later evaluated in the emestedastat trial, a slowing in progression was observed. A trial of emestedastat treatment has also reported anti-depressant activity. Thus, 11β-HSD1 inhibition appears to be a viable therapeutic mechanism. A pivotal, confirmatory trial of emestedastat treatment in 247 patients with mild-moderate AD is due to report topline results in November this year.
- Open Access
- 1 July 2026
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 18 (3)
Elecsys pT181p immunoassay: Clinical performance for ruling out amyloid pathology
INTRODUCTION: Plasma biomarker rule‐out tests can be used early in the Alzheimer's disease (AD) diagnostic pathway to identify people with low likelihood of amyloid pathology. METHODS: A care setting‐agnostic cutoff for the Elecsys ® Phospho‐Tau (181P) plasma (pT181p) immunoassay was determined and validated in two independent, diverse cohorts, representative of real‐world clinical practice ( N = 604; N = 787, respectively). An additional cutoff was assessed in a subset of people reflective of primary care ( n = 312). RESULTS: At a care setting‐agnostic cutoff of 0.934 pg/ml, high negative predictive value (NPV) (93.8%) and acceptable positive predictive value (PPV) (46.6%) were observed against amyloid‐positron emission tomography (PET). A primary care‐specific cutoff of 0.722 pg/ml showed high NPV (97.9%) against amyloid‐PET. Amyloid positivity prevalence for each cutoff population was 22.5% and 13.1%, respectively. DISCUSSION: The pT181p immunoassay is a high‐performance test that may substantially help improve access to amyloid pathology testing for people requiring confirmation, potentially leading to timely clinical decisions and better outcomes.
- 1 July 2026
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 18 (3)
Open AccessElecsys pT181p immunoassay: Clinical performance for ruling out amyloid pathology
INTRODUCTION: Plasma biomarker rule‐out tests can be used early in the Alzheimer's disease (AD) diagnostic pathway to identify people with low likelihood of amyloid pathology. METHODS: A care setting‐agnostic cutoff for the Elecsys ® Phospho‐Tau (181P) plasma (pT181p) immunoassay was determined and validated in two independent, diverse cohorts, representative of real‐world clinical practice ( N = 604; N = 787, respectively). An additional cutoff was assessed in a subset of people reflective of primary care ( n = 312). RESULTS: At a care setting‐agnostic cutoff of 0.934 pg/ml, high negative predictive value (NPV) (93.8%) and acceptable positive predictive value (PPV) (46.6%) were observed against amyloid‐positron emission tomography (PET). A primary care‐specific cutoff of 0.722 pg/ml showed high NPV (97.9%) against amyloid‐PET. Amyloid positivity prevalence for each cutoff population was 22.5% and 13.1%, respectively. DISCUSSION: The pT181p immunoassay is a high‐performance test that may substantially help improve access to amyloid pathology testing for people requiring confirmation, potentially leading to timely clinical decisions and better outcomes.
- Open Access
- 23 June 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (6) , e71609
Cortical gray–white matter contrast alterations precede amyloid‐β positivity and macrostructural changes in older adults without dementia
INTRODUCTION: Early Alzheimer's disease (AD) involves subtle cortical changes that may precede atrophy. Magnetic resonance imaging (MRI) microstructural markers may detect earlier pathology than classical morphometry. METHODS: We analyzed cross‐sectional MRI and amyloid‐β (Aβ) positron emission tomography (PET) data from 1323 non‐demented AMYPAD participants. Cortical volume, thickness, gray–white matter contrast (GWC), and mean diffusivity (MD) were related to global Aβ burden and estimated time to Aβ‐positivity using regression, correlation, and change‐point analyses. RESULTS: Microstructural measures showed stronger age associations than macrostructural measures, whereas all measures were unaffected by apolipoprotein E ( APOE) ‐ε4 carriership. GWC and MD showed minimal overlap with volume and thickness. Higher Aβ burden was most strongly associated with reduced GWC and cortical thinning. Change‐point analyses showed GWC alterations preceded Aβ‐positivity by several years. DISCUSSION: Cortical microstructural MRI, particularly GWC, changes earlier than atrophy and may serve as an early in vivo marker of AD pathology.
- 23 June 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (6) , e71609
Open AccessCortical gray–white matter contrast alterations precede amyloid‐β positivity and macrostructural changes in older adults without dementia
INTRODUCTION: Early Alzheimer's disease (AD) involves subtle cortical changes that may precede atrophy. Magnetic resonance imaging (MRI) microstructural markers may detect earlier pathology than classical morphometry. METHODS: We analyzed cross‐sectional MRI and amyloid‐β (Aβ) positron emission tomography (PET) data from 1323 non‐demented AMYPAD participants. Cortical volume, thickness, gray–white matter contrast (GWC), and mean diffusivity (MD) were related to global Aβ burden and estimated time to Aβ‐positivity using regression, correlation, and change‐point analyses. RESULTS: Microstructural measures showed stronger age associations than macrostructural measures, whereas all measures were unaffected by apolipoprotein E ( APOE) ‐ε4 carriership. GWC and MD showed minimal overlap with volume and thickness. Higher Aβ burden was most strongly associated with reduced GWC and cortical thinning. Change‐point analyses showed GWC alterations preceded Aβ‐positivity by several years. DISCUSSION: Cortical microstructural MRI, particularly GWC, changes earlier than atrophy and may serve as an early in vivo marker of AD pathology.
- Open Access
- 18 May 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (5) , e71462
Speech‐based digital cognitive assessment for clinical trials: Detecting cognitive impairment stages and AD biomarker relations across European cohorts
INTRODUCTION: Early detection of Alzheimer's disease (AD) is critical for timely intervention as disease‐modifying treatments emerge. Speech‐based digital biomarkers offer scalable options for remotely capturing speech‐derived functional changes associated with early cognitive decline, but validation across real‐world populations remains limited. METHODS: We evaluated the speech biomarker for cognition (SB‐C), an automated speech‐derived measure associated with cognitive status, in 736 participants across five European cohorts (Barcelonaβeta Brain Research Center's Alzheimer's at‐risk cohort, European Prevention of Alzheimer's Dementia Scotland, Dementia Study of Cognitive and Biomarker Dynamics, Longitudinal Cognitive Impairment and Dementia Study, and Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably [BioFINDER‐Primary Care]). Participants completed verbal learning and semantic fluency tasks via automated phone or app‐based platforms. SB‐C performance was compared to Mini‐Mental State Examination, Clinical Dementia Rating, Preclinical Alzheimer Cognitive Composite 5, and cerebrospinal fluid amyloid beta and phosphorylated tau181 biomarker status. RESULTS: SB‐C significantly differentiated cognitively unimpaired and impaired groups ( P < 0.001), correlated with standard cognitive measures, and showed moderate‐to‐high area under the curve (0.56–0.82) for classifying biomarker positivity, with strongest results in BioFINDER‐Primary Care. DISCUSSION: SB‐C is a scalable, remote speech‐derived marker associated with cognitive status and AD biomarker group differences.
- 18 May 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (5) , e71462
Open AccessSpeech‐based digital cognitive assessment for clinical trials: Detecting cognitive impairment stages and AD biomarker relations across European cohorts
INTRODUCTION: Early detection of Alzheimer's disease (AD) is critical for timely intervention as disease‐modifying treatments emerge. Speech‐based digital biomarkers offer scalable options for remotely capturing speech‐derived functional changes associated with early cognitive decline, but validation across real‐world populations remains limited. METHODS: We evaluated the speech biomarker for cognition (SB‐C), an automated speech‐derived measure associated with cognitive status, in 736 participants across five European cohorts (Barcelonaβeta Brain Research Center's Alzheimer's at‐risk cohort, European Prevention of Alzheimer's Dementia Scotland, Dementia Study of Cognitive and Biomarker Dynamics, Longitudinal Cognitive Impairment and Dementia Study, and Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably [BioFINDER‐Primary Care]). Participants completed verbal learning and semantic fluency tasks via automated phone or app‐based platforms. SB‐C performance was compared to Mini‐Mental State Examination, Clinical Dementia Rating, Preclinical Alzheimer Cognitive Composite 5, and cerebrospinal fluid amyloid beta and phosphorylated tau181 biomarker status. RESULTS: SB‐C significantly differentiated cognitively unimpaired and impaired groups ( P < 0.001), correlated with standard cognitive measures, and showed moderate‐to‐high area under the curve (0.56–0.82) for classifying biomarker positivity, with strongest results in BioFINDER‐Primary Care. DISCUSSION: SB‐C is a scalable, remote speech‐derived marker associated with cognitive status and AD biomarker group differences.
- Open Access
- 1 April 2025
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 17 (2) , e70065
The impact of mild cognitive impairment on healthcare utilization and costs: A UK Biobank study
INTRODUCTION: Mild cognitive impairment (MCI) is common in older adults, but the burden on patients and health systems is not well understood. We aimed to estimate the impact of MCI on healthcare utilization and costs. METHODS: This was a matched cohort study in UK Biobank comparing healthcare costs and Alzheimer's disease (AD) dementia incidence rates in participants with MCI to propensity score‐matched participants without MCI. RESULTS: Of 164,508 eligible participants, 6605(4%) had cognitive testing scores consistent with MCI. Ten‐year inpatient costs were 7.6% higher in MCI versus matched no‐MCI participants, while 6‐year primary care costs were 9.1% higher. Among MCI participants, AD dementia incidence rates were substantially higher than in non‐MCI participants (7.2 5‐year incidence rate ratio 95% CI: 3.3 to 15.7), and eventual AD dementia accrued higher additional inpatient costs (mean £20,199) over 10 years. DISCUSSION: MCI is characterized by modestly higher healthcare utilization and costs. Subsequent AD dementia diagnosis was strongly associated with costs. Highlights: Baseline cognitive tests identified individuals with all‐cause MCI in the UK Biobank. We compared individuals with MCI to propensity score‐matched participants without MCI. Inpatient costs were 7.6% higher over 10 years, and primary care costs were 9.1% higher over 6 years for participants with MCI. AD dementia incidence rate ratio was 7.2 higher in participants with MCI. Among MCI participants, eventual AD dementia was a key driver of costs resulting in higher inpatient costs (mean £20,199) over 10 years.
- 1 April 2025
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 17 (2) , e70065
Open AccessThe impact of mild cognitive impairment on healthcare utilization and costs: A UK Biobank study
INTRODUCTION: Mild cognitive impairment (MCI) is common in older adults, but the burden on patients and health systems is not well understood. We aimed to estimate the impact of MCI on healthcare utilization and costs. METHODS: This was a matched cohort study in UK Biobank comparing healthcare costs and Alzheimer's disease (AD) dementia incidence rates in participants with MCI to propensity score‐matched participants without MCI. RESULTS: Of 164,508 eligible participants, 6605(4%) had cognitive testing scores consistent with MCI. Ten‐year inpatient costs were 7.6% higher in MCI versus matched no‐MCI participants, while 6‐year primary care costs were 9.1% higher. Among MCI participants, AD dementia incidence rates were substantially higher than in non‐MCI participants (7.2 5‐year incidence rate ratio 95% CI: 3.3 to 15.7), and eventual AD dementia accrued higher additional inpatient costs (mean £20,199) over 10 years. DISCUSSION: MCI is characterized by modestly higher healthcare utilization and costs. Subsequent AD dementia diagnosis was strongly associated with costs. Highlights: Baseline cognitive tests identified individuals with all‐cause MCI in the UK Biobank. We compared individuals with MCI to propensity score‐matched participants without MCI. Inpatient costs were 7.6% higher over 10 years, and primary care costs were 9.1% higher over 6 years for participants with MCI. AD dementia incidence rate ratio was 7.2 higher in participants with MCI. Among MCI participants, eventual AD dementia was a key driver of costs resulting in higher inpatient costs (mean £20,199) over 10 years.
- 10 January 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-6
Investigating the Relationship between Signs of Depression and Alzheimer's Dementia in Speech
Depression and Alzheimer's dementia frequently co-occur, with depression often occurring at early stages of Alzheimer's disease (AD). We investigate whether knowledge of a person's depression score gained through analysis of acoustic features of the person's speech can help detect AD. We analysed data from 239 participants, where $n=162$ individuals had a clinical diagnosis of AD, to explore correlations between depression scores, cognitive test scores and AD status. First, we created multilayer perceptron models for depression assessment using speech features extracted through our active data representation method and wav2vec features. We then used outputs from the depression models as predictors in our Alzheimer's detection models. Depression scores were strongly correlated with Alzheimer's diagnosis in this data set (Spearman's correlation $r = -0.610$ and $r = -0.536,\ p < 0.01$ for correlations between depression scores and diagnosis and cognitive test scores, respectively). We found that depression scores could predict AD fairly accurately $(Acc=0.84)$, and that depression could be detected in speech with moderate accuracy $(Acc=0.79)$. Using these predictions and acoustic features, our dementia model reached $Acc=0.70$. We also investigated classification of AD from speech in the presence and absence of depression, obtaining the same level of accuracy for this imbalanced prediction task.- 10 January 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-6
Investigating the Relationship between Signs of Depression and Alzheimer's Dementia in Speech
Depression and Alzheimer's dementia frequently co-occur, with depression often occurring at early stages of Alzheimer's disease (AD). We investigate whether knowledge of a person's depression score gained through analysis of acoustic features of the person's speech can help detect AD. We analysed data from 239 participants, where $n=162$ individuals had a clinical diagnosis of AD, to explore correlations between depression scores, cognitive test scores and AD status. First, we created multilayer perceptron models for depression assessment using speech features extracted through our active data representation method and wav2vec features. We then used outputs from the depression models as predictors in our Alzheimer's detection models. Depression scores were strongly correlated with Alzheimer's diagnosis in this data set (Spearman's correlation $r = -0.610$ and $r = -0.536,\ p < 0.01$ for correlations between depression scores and diagnosis and cognitive test scores, respectively). We found that depression scores could predict AD fairly accurately $(Acc=0.84)$, and that depression could be detected in speech with moderate accuracy $(Acc=0.79)$. Using these predictions and acoustic features, our dementia model reached $Acc=0.70$. We also investigated classification of AD from speech in the presence and absence of depression, obtaining the same level of accuracy for this imbalanced prediction task.- Open Access
- 8 October 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (7) , e209801
Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia
Vascular risk factors (VRFs) and cerebral small vessel disease (cSVD) are common in patients with Alzheimer disease (AD). It remains unclear whether this coexistence reflects shared risk factors or a mechanistic relationship and whether vascular and amyloid pathologies have independent or synergistic influence on subsequent AD pathophysiology in preclinical stages. We investigated links between VRFs, cSVD, and amyloid levels (Aβ1-42) and their combined effect on downstream AD biomarkers, that is, CSF hyperphosphorylated tau (P-tau181), atrophy, and cognition. This retrospective study included nondemented participants (Clinical Dementia Rating < 1) from the European Prevention of Alzheimer's Dementia (EPAD) cohort and assessed VRFs with the Framingham risk score (FRS) and cSVD features on MRI using visual scales and white matter hyperintensity volumes. After preliminary linear analysis, we used structural equation modeling (SEM) to create a "cSVD severity" latent variable and assess the direct and indirect effects of FRS and cSVD severity on Aβ1-42, P-tau181, gray matter volume (baseline and longitudinal), and cognitive performance (baseline and longitudinal). A total cohort of 1,592 participants were evaluated (mean age = 65.5 ± 7.4 years; 56.16% F). We observed positive associations between FRS and all cSVD features (all p < 0.05) and a negative association between FRS and Aβ1-42 (β = -0.04 ± 0.01). All cSVD features were negatively associated with CSF Aβ1-42 (all p < 0.05). Using SEM, the cSVD severity fully mediated the association between FRS and CSF Aβ1-42 (indirect effect: β = -0.03 ± 0.01), also when omitting vascular amyloid-related markers. We observed a significant indirect effect of cSVD severity on P-tau181 (indirect effect: β = 0.12 ± 0.03), baseline and longitudinal gray matter volume (indirect effect: β = -0.10 ± 0.03; β = -0.12 ± 0.05), and baseline cognitive performance (indirect effect: β = -0.16 ± 0.03) through CSF Aβ1-42. In a large nondemented population, our findings suggest that cSVD is a mediator of the relationship between VRFs and CSF Aβ1-42 and affects downstream neurodegeneration and cognitive impairment. We provide evidence of VRFs indirectly affecting the pathogenesis of AD, highlighting the importance of considering cSVD burden in memory clinics for AD risk evaluation and as an early window for intervention. These results stress the role of VRFs and cerebrovascular pathology as key biomarkers for accurate design of anti-amyloid clinical trials and offer new perspectives for patient stratification.
- 8 October 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (7) , e209801
Open AccessAssociation of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia
Vascular risk factors (VRFs) and cerebral small vessel disease (cSVD) are common in patients with Alzheimer disease (AD). It remains unclear whether this coexistence reflects shared risk factors or a mechanistic relationship and whether vascular and amyloid pathologies have independent or synergistic influence on subsequent AD pathophysiology in preclinical stages. We investigated links between VRFs, cSVD, and amyloid levels (Aβ1-42) and their combined effect on downstream AD biomarkers, that is, CSF hyperphosphorylated tau (P-tau181), atrophy, and cognition. This retrospective study included nondemented participants (Clinical Dementia Rating < 1) from the European Prevention of Alzheimer's Dementia (EPAD) cohort and assessed VRFs with the Framingham risk score (FRS) and cSVD features on MRI using visual scales and white matter hyperintensity volumes. After preliminary linear analysis, we used structural equation modeling (SEM) to create a "cSVD severity" latent variable and assess the direct and indirect effects of FRS and cSVD severity on Aβ1-42, P-tau181, gray matter volume (baseline and longitudinal), and cognitive performance (baseline and longitudinal). A total cohort of 1,592 participants were evaluated (mean age = 65.5 ± 7.4 years; 56.16% F). We observed positive associations between FRS and all cSVD features (all p < 0.05) and a negative association between FRS and Aβ1-42 (β = -0.04 ± 0.01). All cSVD features were negatively associated with CSF Aβ1-42 (all p < 0.05). Using SEM, the cSVD severity fully mediated the association between FRS and CSF Aβ1-42 (indirect effect: β = -0.03 ± 0.01), also when omitting vascular amyloid-related markers. We observed a significant indirect effect of cSVD severity on P-tau181 (indirect effect: β = 0.12 ± 0.03), baseline and longitudinal gray matter volume (indirect effect: β = -0.10 ± 0.03; β = -0.12 ± 0.05), and baseline cognitive performance (indirect effect: β = -0.16 ± 0.03) through CSF Aβ1-42. In a large nondemented population, our findings suggest that cSVD is a mediator of the relationship between VRFs and CSF Aβ1-42 and affects downstream neurodegeneration and cognitive impairment. We provide evidence of VRFs indirectly affecting the pathogenesis of AD, highlighting the importance of considering cSVD burden in memory clinics for AD risk evaluation and as an early window for intervention. These results stress the role of VRFs and cerebrovascular pathology as key biomarkers for accurate design of anti-amyloid clinical trials and offer new perspectives for patient stratification.
- Open Access
- 3 September 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (17) , 5228
Differences in Grey Matter Concentrations and Functional Connectivity between Young Carriers and Non-Carriers of the APOE ε4 Genotype
Background: The pathophysiology of Alzheimer’s disease (AD) may begin developing years or even decades prior to the manifestation of its first symptoms. The APOE ε4 genotype is a prominent genetic risk for AD that has been found to be associated with brain changes across the lifespan since early adulthood. Thus, studying brain changes that may occur in young adults with an APOE ε4 status is highly relevant. Objective: Examine potential differences in grey matter (GM) and functional connectivity (FC) in brains of cognitively healthy young APOE ε4 carriers and non-carriers, denoted here as ε4(+) and ε4(−), respectively. Methods: Three Tesla magnetic resonance imaging (MRI) brain scans were acquired from cognitively healthy young participants aged approximately 20 years (n = 151). Voxel-based morphometry (VBM) analysis was employed to identify potential structural differences in GM between ε4(+) and ε4(−). In a subsequent seed-based connectivity (SBC) analysis, brain regions that structurally differed in the VBM analysis were considered as seeds and correlated with all the remaining voxels across the brains to then measure the differences in FC between groups. Results: The VBM analysis suggested that ε4(+) (n = 28) had greater GM densities relative to ε4(−) (n = 123) in the left hippocampus and the left posterior insula (puncorr < 0.001). However, the effect did not survive the correction for multiple comparisons, suggesting minimal structural differences in this age range. In contrast, the SBC analysis indicated that ε4(+) exhibited significantly decreased FC between the left hippocampus and areas of the left middle temporal gyrus (n = 27) compared to ε4(−) (n = 102). These results remained significant after multiple comparisons (pFDR < 0.05). Lastly, no statistically significant differences in FC between groups were observed for the left insular seed (pFDR > 0.05). Discussion: These results suggest early structural and functional brain changes associated with the APOE ε4 genotype on young adults. Yet, they must be cautiously interpreted and contrasted with both older adults with genetic risk for AD and patients diagnosed with AD.
- 3 September 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (17) , 5228
Open AccessDifferences in Grey Matter Concentrations and Functional Connectivity between Young Carriers and Non-Carriers of the APOE ε4 Genotype
Background: The pathophysiology of Alzheimer’s disease (AD) may begin developing years or even decades prior to the manifestation of its first symptoms. The APOE ε4 genotype is a prominent genetic risk for AD that has been found to be associated with brain changes across the lifespan since early adulthood. Thus, studying brain changes that may occur in young adults with an APOE ε4 status is highly relevant. Objective: Examine potential differences in grey matter (GM) and functional connectivity (FC) in brains of cognitively healthy young APOE ε4 carriers and non-carriers, denoted here as ε4(+) and ε4(−), respectively. Methods: Three Tesla magnetic resonance imaging (MRI) brain scans were acquired from cognitively healthy young participants aged approximately 20 years (n = 151). Voxel-based morphometry (VBM) analysis was employed to identify potential structural differences in GM between ε4(+) and ε4(−). In a subsequent seed-based connectivity (SBC) analysis, brain regions that structurally differed in the VBM analysis were considered as seeds and correlated with all the remaining voxels across the brains to then measure the differences in FC between groups. Results: The VBM analysis suggested that ε4(+) (n = 28) had greater GM densities relative to ε4(−) (n = 123) in the left hippocampus and the left posterior insula (puncorr < 0.001). However, the effect did not survive the correction for multiple comparisons, suggesting minimal structural differences in this age range. In contrast, the SBC analysis indicated that ε4(+) exhibited significantly decreased FC between the left hippocampus and areas of the left middle temporal gyrus (n = 27) compared to ε4(−) (n = 102). These results remained significant after multiple comparisons (pFDR < 0.05). Lastly, no statistically significant differences in FC between groups were observed for the left insular seed (pFDR > 0.05). Discussion: These results suggest early structural and functional brain changes associated with the APOE ε4 genotype on young adults. Yet, they must be cautiously interpreted and contrasted with both older adults with genetic risk for AD and patients diagnosed with AD.
- Open Access
Association between choroidal microvasculature in the eye and Alzheimer’s disease risk in cognitively healthy midlife adults: a pilot study
Objective To explore associations between measurements of the ocular microvasculature in the choroid (a highly vascularised layer posterior to the retina) and genetic Alzheimer’s disease risk. Methods We measured the choroidal vasculature appearing in optical coherence tomography scans of 69 healthy, mid-life individuals in the PREVENT cohort. The cohort was prospectively split into low, medium, and high-risk groups based on the presence of known risk factors (APOE4 genotype and family history of dementia). We used ordinal logistic regression to test for cross-sectional associations between choroidal measurements and pre-determined risk of future Alzheimer’s disease. Results We observed progressively increased choroidal vasculature between ordinal risk groups, and all choroidal measurements were significantly associated with risk group prediction. APOE4 carriers had significantly thicker choroids and larger vascular tissue compared to non-carriers. Similar trends were observed for those with a family history of dementia. In our sample, a 0.16 mm2 increase in choroidal vascular area was associated with a 2-fold increase in the likelihood of having one or more markers of Alzheimer’s disease risk, compared with none. Conclusions Our results suggest a potential link between the choroidal vasculature and risk of Alzheimer’s disease. However, these findings are exploratory and should be replicated in a larger, more diverse sample.
Open AccessAssociation between choroidal microvasculature in the eye and Alzheimer’s disease risk in cognitively healthy midlife adults: a pilot study
Objective To explore associations between measurements of the ocular microvasculature in the choroid (a highly vascularised layer posterior to the retina) and genetic Alzheimer’s disease risk. Methods We measured the choroidal vasculature appearing in optical coherence tomography scans of 69 healthy, mid-life individuals in the PREVENT cohort. The cohort was prospectively split into low, medium, and high-risk groups based on the presence of known risk factors (APOE4 genotype and family history of dementia). We used ordinal logistic regression to test for cross-sectional associations between choroidal measurements and pre-determined risk of future Alzheimer’s disease. Results We observed progressively increased choroidal vasculature between ordinal risk groups, and all choroidal measurements were significantly associated with risk group prediction. APOE4 carriers had significantly thicker choroids and larger vascular tissue compared to non-carriers. Similar trends were observed for those with a family history of dementia. In our sample, a 0.16 mm2 increase in choroidal vascular area was associated with a 2-fold increase in the likelihood of having one or more markers of Alzheimer’s disease risk, compared with none. Conclusions Our results suggest a potential link between the choroidal vasculature and risk of Alzheimer’s disease. However, these findings are exploratory and should be replicated in a larger, more diverse sample.
- Open Access
- 3 May 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 6 (3) , fcae189
The PREVENT dementia programme: baseline demographic, lifestyle, imaging and cognitive data from a midlife cohort study investigating risk factors for dementia
PREVENT is a multi-centre prospective cohort study in the UK and Ireland that aims to examine midlife risk factors for dementia and identify and describe the earliest indices of disease development. The PREVENT dementia programme is one of the original epidemiological initiatives targeting midlife as a critical window for intervention in neurodegenerative conditions. This paper provides an overview of the study protocol and presents the first summary results from the initial baseline data to describe the cohort. Participants in the PREVENT cohort provide demographic data, biological samples (blood, saliva, urine and optional cerebrospinal fluid), lifestyle and psychological questionnaires, undergo a comprehensive cognitive test battery and are imaged using multi-modal 3-T MRI scanning, with both structural and functional sequences. The PREVENT cohort governance structure is described, which includes a steering committee, a scientific advisory board and core patient and public involvement groups. A number of sub-studies that supplement the main PREVENT cohort are also described. The PREVENT cohort baseline data include 700 participants recruited between 2014 and 2020 across five sites in the UK and Ireland (Cambridge, Dublin, Edinburgh, London and Oxford). At baseline, participants had a mean age of 51.2 years (range 40–59, SD ± 5.47), with the majority female (n = 433, 61.9%). There was a near equal distribution of participants with and without a parental history of dementia (51.4% versus 48.6%) and a relatively high prevalence of APOEɛ4 carriers (n = 264, 38.0%). Participants were highly educated (16.7 ± 3.44 years of education), were mainly of European Ancestry (n = 672, 95.9%) and were cognitively healthy as measured by the Addenbrookes Cognitive Examination-III (total score 95.6 ± 4.06). Mean white matter hyperintensity volume at recruitment was 2.26 ± 2.77 ml (median = 1.39 ml), with hippocampal volume being 8.15 ± 0.79 ml. There was good representation of known dementia risk factors in the cohort. The PREVENT cohort offers a novel data set to explore midlife risk factors and early signs of neurodegenerative disease. Data are available open access at no cost via the Alzheimer’s Disease Data Initiative platform and Dementia Platforms UK platform pending approval of the data access request from the PREVENT steering group committee.
- 3 May 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 6 (3) , fcae189
Open AccessThe PREVENT dementia programme: baseline demographic, lifestyle, imaging and cognitive data from a midlife cohort study investigating risk factors for dementia
PREVENT is a multi-centre prospective cohort study in the UK and Ireland that aims to examine midlife risk factors for dementia and identify and describe the earliest indices of disease development. The PREVENT dementia programme is one of the original epidemiological initiatives targeting midlife as a critical window for intervention in neurodegenerative conditions. This paper provides an overview of the study protocol and presents the first summary results from the initial baseline data to describe the cohort. Participants in the PREVENT cohort provide demographic data, biological samples (blood, saliva, urine and optional cerebrospinal fluid), lifestyle and psychological questionnaires, undergo a comprehensive cognitive test battery and are imaged using multi-modal 3-T MRI scanning, with both structural and functional sequences. The PREVENT cohort governance structure is described, which includes a steering committee, a scientific advisory board and core patient and public involvement groups. A number of sub-studies that supplement the main PREVENT cohort are also described. The PREVENT cohort baseline data include 700 participants recruited between 2014 and 2020 across five sites in the UK and Ireland (Cambridge, Dublin, Edinburgh, London and Oxford). At baseline, participants had a mean age of 51.2 years (range 40–59, SD ± 5.47), with the majority female (n = 433, 61.9%). There was a near equal distribution of participants with and without a parental history of dementia (51.4% versus 48.6%) and a relatively high prevalence of APOEɛ4 carriers (n = 264, 38.0%). Participants were highly educated (16.7 ± 3.44 years of education), were mainly of European Ancestry (n = 672, 95.9%) and were cognitively healthy as measured by the Addenbrookes Cognitive Examination-III (total score 95.6 ± 4.06). Mean white matter hyperintensity volume at recruitment was 2.26 ± 2.77 ml (median = 1.39 ml), with hippocampal volume being 8.15 ± 0.79 ml. There was good representation of known dementia risk factors in the cohort. The PREVENT cohort offers a novel data set to explore midlife risk factors and early signs of neurodegenerative disease. Data are available open access at no cost via the Alzheimer’s Disease Data Initiative platform and Dementia Platforms UK platform pending approval of the data access request from the PREVENT steering group committee.